Successfully reported this slideshow.
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Leadto Erosion of Bra...
Reasons to buyAlign their product portfolio to the markets with high growth potential Build effective strategies to launch...
3.6.7 Pravachol (pravastatin Sodium) 244 Statins Market To 2018 - Statins Market In The Us 254.1 Market 254.2 Annual Cost ...
8.2.1 Company Overview 458.2.2 Swot Analysis 458.3 Merck & Co Inc 468.3.1 Company Overview 468.3.2 Swot Analysis 468.4 Nov...
90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sale...
Upcoming SlideShare
Loading in …5
×

Statins Market Trends to 2018 | Researchmoz.us

477 views

Published on

GBI Research, the leading business intelligence provider, has released its latest research, Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share, which provides insights into the global statins market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia. The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan

  • Be the first to comment

  • Be the first to like this

Statins Market Trends to 2018 | Researchmoz.us

  1. 1. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Leadto Erosion of Brand ShareStatins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Leadto Erosion of Brand ShareSummaryGBI Research, the leading business intelligence provider, has released its latest research, Statins Market to2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of BrandShare, which provides insights into the global statins market until 2018. The report is built using data andinformation sourced from proprietary databases, primary and secondary research, and in-house analysis byGBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins marketfor dyslipidemia. The report gives insights into the share of generics in the global statins market for the years2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top fivecountries of Europe (The UK, France, Germany, Spain and Italy), and Japan. In addition to the global marketlandscape for statins, the report also provides details of the geographical distribution of statins sales in themajor markets, including the US, the top five countries of Europe, and Japan. The report also includes insightsinto the statins R&D product pipeline, and explores the competitive landscape, including major players in thestatins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing andco-development deals that have taken place in the statins market.Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The NationalCholesterol Education Program (NECP) and European Society of Cardiology/European AtherosclerosisSociety (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy forthe treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to declineat a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2billion by 2018. The highly consolidated statins market is expected to become increasingly competitive in theforecast period, with the patent expiries of (atorvastatin calcium), Vytorin (Ezetimibe/simvastatin), Lescol(fluvastatin) and Crestor (rosuvastatin), followed by severe generic erosion. GBI Research estimates that thegeneric sector in the global statins market will grow significantly in the future and will pose tough competitionto new molecules.ScopeData and analysis on the statins market in the leading geographies of the world the US, the UK, Germany,France, Italy, Spain, and Japan. Annualized market data for the statins market from 2004 to 2011, withforecasts to 2018. Market data on the geographical landscape and therapeutic landscape, including market size,market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population,treatment-seeking population, diagnosis population and prescription population. Share of generics in theglobal statins market. Key drivers and restraints that have had a significant impact on the global statinsmarket. The competitive landscape of the global statins market, including top companies benchmarking. Thekey companies studied in this report are Pfizer, AstraZeneca, Merck and Novartis. Key M&A activities andlicensing agreements that took place in the statins market.Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  2. 2. Reasons to buyAlign their product portfolio to the markets with high growth potential Build effective strategies to launchtheir pipeline products by identifying potential geographies Exploit in-licensing and out-licensingopportunities by identifying products that might fill their portfolio gaps Develop key strategic initiatives bystudying the key strategies of top competitors Devise more tailored country-specific strategies through theunderstanding of key drivers and barriers and the market potential of each indication for different territoriesDevelop market-entry and market expansion strategies by identifying the geographic markets poised for stronggrowth Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-classmolecules which are safer and more efficacioustable Of Contents1 Table Of Contents1 Table Of Contents 51.1 List Of Tables 71.2 List Of Figures 72 Statins Market To 2018 - Introduction 83 Statins Market To 2018 - Global Statins Market 93.1 Introduction 93.2 Global Market Forecast 103.2.1 Branded And Generic Market Share 123.3 Annual Cost Of Treatment 133.4 Treatment Usage Patterns 143.4.1 Disease Population 153.4.2 Treatment Seeking Population 153.4.3 Diagnosed Population 153.4.4 Prescription Population 153.5 Drivers And Restraints To The Statins Market 163.5.1 Drivers To The Statins Market 163.5.2 Restraints To The Statins Market 173.6 Major Marketed Products 193.6.1 Crestor (rosuvastatin Calcium) 193.6.2 Lipitor (atorvastatin Calcium) 203.6.3 Vytorin (ezetimibe/simvastatin) 213.6.4 Zocor (simvastatin) 223.6.5 Livalo (pitavastatin Calcium) 223.6.6 Lescol Xl (fluvastatin Sodium) 23Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  3. 3. 3.6.7 Pravachol (pravastatin Sodium) 244 Statins Market To 2018 - Statins Market In The Us 254.1 Market 254.2 Annual Cost Of Therapy (act) 274.3 Treatment Usage Pattern 284.3.1 Diseased Population 294.3.2 Treatment Seeking Population 294.3.3 Diagnosed Population 294.3.4 Patients On Statins Therapy 295 Statins Market To 2018 - Statins Market In The Top Five Countries Of Europe 305.1 Market 305.2 Annual Cost Of Therapy 335.3 Treatment Usage Pattern 345.3.1 Diseased Population 355.3.2 Treatment Seeking Population 355.3.3 Diagnosed Population 355.3.4 Patients On Statins Therapy 356 Statins Market To 2018 - Statins Market In Japan 366.1 Market 366.2 Annual Cost Of Therapy 386.3 Treatment Usage Pattern 406.3.1 Diseased Population 416.3.2 Treatment Seeking Population 416.3.3 Diagnosed Population 416.3.4 Patients On Statins Therapy 417 Statins Market To 2018 - Product Pipeline Anlaysis 427.1 Introduction 427.2 Pipeline Analysis 428 Statins Market To 2018 - Competitive Landscape 438.1 Pfizer Inc. 448.1.1 Company Overview 448.1.2 Swot Analysis 448.2 Astrazeneca Plc (astrazeneca) 45Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  4. 4. 8.2.1 Company Overview 458.2.2 Swot Analysis 458.3 Merck & Co Inc 468.3.1 Company Overview 468.3.2 Swot Analysis 468.4 Novartis Ag (novartis) 478.4.1 Company Overview 478.4.2 Swot Analysis 479 Statins Market To 2018 - Strategic Consolidation 489.1 Merger And Acquisition (m&a) Deals 489.2 Licensing Deals 499.2.1 Licensing Deals By Geography 499.3 Co-development Deals 5110 Statins Market To 2018 - Appendix 5210.1 Market Definitions 5210.2 Abbreviations 5210.3 Bibliography 5510.4 Research Methodology 5610.4.1 Coverage 5610.4.2 Secondary Research 5610.4.3 Primary Research 5710.4.4 Therapeutic Landscape 5710.4.5 Geographical Landscape 6010.4.6 Pipeline Analysis 6010.4.7 Competitive Landscape 6010.5 Expert Panel Validation 6010.6 Contact Us 6010.7 Disclaimer 60About Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMozStatins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
  5. 5. 90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

×